ES2163019T3 - Derivados de 2-(1h-4(5)-imidazolil)ciclopropilo. - Google Patents

Derivados de 2-(1h-4(5)-imidazolil)ciclopropilo.

Info

Publication number
ES2163019T3
ES2163019T3 ES96914788T ES96914788T ES2163019T3 ES 2163019 T3 ES2163019 T3 ES 2163019T3 ES 96914788 T ES96914788 T ES 96914788T ES 96914788 T ES96914788 T ES 96914788T ES 2163019 T3 ES2163019 T3 ES 2163019T3
Authority
ES
Spain
Prior art keywords
methyl
hydrogen
ethyl group
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914788T
Other languages
English (en)
Inventor
James G Phillips
Clark E Tedford
Amin Mohammed Khan
Stephen L Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gliatech Inc
Original Assignee
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliatech Inc filed Critical Gliatech Inc
Application granted granted Critical
Publication of ES2163019T3 publication Critical patent/ES2163019T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION ACTUAL PROPORCIONA COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES H SUB,3} DE LA HISTAMINA, DE FORMULA GENERAL (1.0), EN DONDE R SUB,2} ES UN HIDROGENO O UN GRUPO METILO O ETILO; R SUB,3} ES UN HIDROGENO O GRUPO UN METILO O ETILO; N ES 0, 1, 2, 3, 4, 5, O 6; Y R SUB,1} SE SELECCIONA DEL GRUPO QUE CONSISTE EN (A) C SUB,3} A C SUB,8} CICLOALQUILO; (B) FENIL O FENIL SUSTITUIDO; (C) ALQUILO; D) HETEROCICLICO; (E) DECAHIDRONAFTALENO; Y (F) OCTAHIDROINDENO; CON LA CONDICION DE QUE CUANDO X ES H, A PUEDE SER - CH SUB,2}CH SUB,2} -, COCH SUB,2} -, - CONH -, - CON(CH SUB,3}) -, - CH = CH -, AL}, CH SUB,2} - NH -, - CH SUB,2} - N(CH SUB,3}) -, CH(OH)CH SUB,2} -, - NH - CH SUB,2} -, - N(CH SUB,3}) - CH SUB,2} -, - CH SUB,2}O -, - CH SUB,2}S -, Y - NHCOO -; CUANDO X ES NH SUB,2}, NH(CH SUB,3}), N(CH SUB,3}) SUB,2}, OH, OCH SUB,3}, CH SUB,3}, SH Y SCH SUB,3}; A PUEDE SER - NHCO -, - N(CH SUB,3}) - CO -, - NHCH SUB,2} -, - N(CH SUB,3}) - CH SUB,2} -, - CH = CH -, - COCH SUB,2} -, -CH SUB,2}CH SUB,2} -, - CH(OH)CH SUB,2} -, O BE}; Y CUANDO R SUB,1} Y X TOMADOS JUNTOS DENOTAN UNA ESTRUCTURA SATURADA 5,6 O 6,6 DE ANILLO BICICLICO, X PUEDE SER NH, O, O S. LAS SALES FARMACEUTICAMENTE ACEPTABLES, HIDRATOS, Y ESTEREOISOMEROS INDIVIDUALES DE COMPUESTOS DE FORMULA ESTRUCTURAL (1.0), ASI COMO LAS MEZCLAS DE ESTOS, SE CONTEMPLAN TAMBIEN DENTRO DEL ALCANCE DE LA PRESENTE INVENCION. ESTA INVENCION APORTA TAMBIEN COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN VEHICULO FARMACEUTICAMENTE ACEPTABLE EN COMBINACION CON UNA CANTIDAD EFICAZ DE UN COMPUESTO DE DICHA FORMULA Y UN METODO DE TRATAR PROCESOS PATOLOGICOS EN LOS QUE EL ANTAGONISMO DE LOS RECEPTORES H SUB,3} DE LA HISTAMINA PUEDE SER DE IMPORTANCIA TERAPEUTICA.
ES96914788T 1995-05-30 1996-05-29 Derivados de 2-(1h-4(5)-imidazolil)ciclopropilo. Expired - Lifetime ES2163019T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/453,359 US5652258A (en) 1995-05-30 1995-05-30 2-(4-imidazoyl) cyclopropyl derivatives

Publications (1)

Publication Number Publication Date
ES2163019T3 true ES2163019T3 (es) 2002-01-16

Family

ID=23800267

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914788T Expired - Lifetime ES2163019T3 (es) 1995-05-30 1996-05-29 Derivados de 2-(1h-4(5)-imidazolil)ciclopropilo.

Country Status (17)

Country Link
US (2) US5652258A (es)
EP (1) EP0837679B1 (es)
JP (1) JP2001503013A (es)
KR (1) KR19990022137A (es)
CN (1) CN1100534C (es)
AT (1) ATE207354T1 (es)
AU (1) AU713767B2 (es)
CA (1) CA2222101A1 (es)
DE (1) DE69616328T2 (es)
DK (1) DK0837679T3 (es)
ES (1) ES2163019T3 (es)
FI (1) FI974363A (es)
MX (1) MX9709211A (es)
NO (1) NO975484D0 (es)
NZ (1) NZ308410A (es)
PT (1) PT837679E (es)
WO (1) WO1996038141A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
US6008240A (en) * 1997-12-15 1999-12-28 Gliatech, Inc. 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
JP2002534511A (ja) 1999-01-18 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 置換型イミダゾール、それらの調製及び使用
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6114350A (en) * 1999-04-19 2000-09-05 Nen Life Science Products, Inc. Cyanine dyes and synthesis methods thereof
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6794405B2 (en) 2000-08-17 2004-09-21 Merck & Co., Inc. Alicyclic imidazoles as H3 agents
JP2004506685A (ja) * 2000-08-21 2004-03-04 グリアテツク・インコーポレイテツド 食欲の制御と肥満の治療のためのヒスタミンh3受容体逆アゴニストの使用
WO2002067938A2 (en) * 2000-10-30 2002-09-06 Schering Corporation Treating or reducing the risk of cardiovascular disease
MXPA04005557A (es) * 2002-03-01 2005-05-17 Warner Lambert Co Metodo para tratar la osteoartritis.
CA2555071A1 (en) * 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
EP1720861A2 (en) 2004-02-25 2006-11-15 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
MXPA06011167A (es) 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
US7696234B2 (en) 2004-06-02 2010-04-13 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
JP4942654B2 (ja) 2004-08-23 2012-05-30 イーライ リリー アンド カンパニー ヒスタミンh3受容体薬剤、製剤及び治療的使用
JP5057982B2 (ja) 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー ヒスタミンh3受容体阻害剤、製造及び治療的使用
US7951826B2 (en) * 2005-03-17 2011-05-31 Eli Lilly And Company Pyrrolidine derivatives as histamine H3 receptor antagonists
EP1868991B1 (en) 2005-04-01 2014-07-30 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2007032536A1 (ja) * 2005-09-15 2007-03-22 Banyu Pharmaceutical Co., Ltd. 脂質・糖代謝性疾患の治療剤としてのヒスタミンh3アゴニスト
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CA2849564C (en) 2011-10-20 2020-10-20 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
BR112014009306B1 (pt) 2011-10-20 2021-07-20 Oryzon Genomics S.A. Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) * 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
EP0573542B1 (en) * 1991-02-27 1997-10-15 Seed Capital Investments( Sci) B.V. Imidazole-derivatives having antagonistic activity on the histamine h3-receptor
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives

Also Published As

Publication number Publication date
KR19990022137A (ko) 1999-03-25
EP0837679A4 (en) 1999-03-03
MX9709211A (es) 1998-07-31
WO1996038141A1 (en) 1996-12-05
JP2001503013A (ja) 2001-03-06
EP0837679B1 (en) 2001-10-24
FI974363A0 (fi) 1997-11-28
EP0837679A1 (en) 1998-04-29
ATE207354T1 (de) 2001-11-15
NZ308410A (en) 2001-06-29
CN1192143A (zh) 1998-09-02
DK0837679T3 (da) 2002-02-11
CN1100534C (zh) 2003-02-05
AU5804796A (en) 1996-12-18
NO975484D0 (no) 1997-11-28
PT837679E (pt) 2002-03-28
US5990317A (en) 1999-11-23
CA2222101A1 (en) 1996-12-05
DE69616328D1 (de) 2001-11-29
US5652258A (en) 1997-07-29
FI974363A (fi) 1997-11-28
DE69616328T2 (de) 2002-07-04
AU713767B2 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
ES2163019T3 (es) Derivados de 2-(1h-4(5)-imidazolil)ciclopropilo.
DE69619381T2 (de) 1h-4(5)substituierte imidazolderivate
ES2176204T3 (es) Antidepresivos que contienen un derivado de xantina.
CA2295106A1 (en) 3-anilino-2-cycloalkenone derivatives
ES2149777T3 (es) Derivados de triazol que tienen actividad antifungica.
IT1209512B (it) Procedimento selettivo per il blocco di ricettori di 5ht2.
IE840182L (en) Des-proline vasopressin antagonists
NO974749D0 (no) Fremgangsmåte for fremstilling av 2,2'-bipyrrolyl-pyrrometen (prodigiosiner) -derivater
YU45582B (sh) Postopek za pripravo derivatov arilamina
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.
DE69712325D1 (de) Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
FI932744A0 (fi) Framstaellningsmetod och mellanprodukter foer bis-azabicykliska aongestfoermildrande aemnen
ES8506581A1 (es) Procedimiento de preparar 2-trifluometil-4, 6-dinitrofenol y sus derivados
TR199901932T2 (xx) CETP aktivitesi inhibitörleri.
DK0850217T3 (da) Fremgangsmåde til fremstilling af arylalkynyl-N-hydroxy-carbamid-derivater med lipoxygenaseinhibitor-aktivitet

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 837679

Country of ref document: ES